PainReform (PRFX) Competitors $1.01 -0.39 (-27.86%) (As of 02:10 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PRFX vs. CMND, DRMA, NTBL, GRTX, JMAC, MAAQ, SLRX, SONN, ENTO, and AKANShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Clearmind Medicine (CMND), Dermata Therapeutics (DRMA), Notable Labs (NTBL), Galera Therapeutics (GRTX), Maxpro Capital Acquisition (JMAC), Mana Capital Acquisition (MAAQ), Salarius Pharmaceuticals (SLRX), Sonnet BioTherapeutics (SONN), Entero Therapeutics (ENTO), and Akanda (AKAN). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Clearmind Medicine Dermata Therapeutics Notable Labs Galera Therapeutics Maxpro Capital Acquisition Mana Capital Acquisition Salarius Pharmaceuticals Sonnet BioTherapeutics Entero Therapeutics Akanda Clearmind Medicine (NASDAQ:CMND) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Do insiders and institutionals hold more shares of CMND or PRFX? 96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer CMND or PRFX? In the previous week, PainReform had 2 more articles in the media than Clearmind Medicine. MarketBeat recorded 2 mentions for PainReform and 0 mentions for Clearmind Medicine. PainReform's average media sentiment score of 0.30 beat Clearmind Medicine's score of -1.00 indicating that PainReform is being referred to more favorably in the news media. Company Overall Sentiment Clearmind Medicine Negative PainReform Neutral Which has stronger earnings and valuation, CMND or PRFX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearmind MedicineN/AN/A-$8.62MN/AN/APainReformN/AN/A-$9.34M-$36.83-0.03 Do analysts rate CMND or PRFX? PainReform has a consensus price target of $2.00, indicating a potential upside of 98.02%. Given PainReform's stronger consensus rating and higher possible upside, analysts plainly believe PainReform is more favorable than Clearmind Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, CMND or PRFX? Clearmind Medicine has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Is CMND or PRFX more profitable? Clearmind Medicine's return on equity of -238.73% beat PainReform's return on equity.Company Net Margins Return on Equity Return on Assets Clearmind MedicineN/A -238.73% -102.10% PainReform N/A -450.64%-241.33% Does the MarketBeat Community prefer CMND or PRFX? PainReform received 3 more outperform votes than Clearmind Medicine when rated by MarketBeat users. CompanyUnderperformOutperformClearmind MedicineN/AN/APainReformOutperform Votes375.00% Underperform Votes125.00% SummaryPainReform beats Clearmind Medicine on 6 of the 11 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$586,000.00$6.41B$4.99B$8.73BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.0310.02131.5917.49Price / SalesN/A322.071,207.5889.33Price / CashN/A22.1633.2732.46Price / Book0.045.504.684.66Net Income-$9.34M$152.72M$117.80M$224.87M7 Day Performance73.24%-4.08%-2.38%-2.25%1 Month Performance53.03%-8.51%-3.97%-0.19%1 Year Performance-49.75%29.22%29.85%24.36% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform1.9388 of 5 stars$1.01-27.9%$2.00+98.0%-34.3%$586,000.00N/A-0.034Gap DownHigh Trading VolumeCMNDClearmind Medicine0.3055 of 5 stars$1.38+2.8%N/A-65.6%$2.33MN/A0.00N/ANegative NewsDRMADermata Therapeutics2.2071 of 5 stars$1.14+5.6%$6.00+426.3%-89.6%$2.33MN/A-0.078NTBLNotable LabsN/A$0.25-27.7%$7.00+2,723.7%-92.4%$2.24M$313,000.000.0040Gap DownHigh Trading VolumeGRTXGalera TherapeuticsN/A$0.04+2.2%N/A-71.3%$2.23MN/A-0.0730Gap UpJMACMaxpro Capital AcquisitionN/A$0.16-15.4%N/A-74.5%$2.21MN/A0.002,021Gap DownHigh Trading VolumeMAAQMana Capital AcquisitionN/A$0.26-3.7%N/A-73.1%$2.11MN/A0.001High Trading VolumeSLRXSalarius Pharmaceuticals0.2054 of 5 stars$1.40-0.7%N/A-74.5%$2.02M$1.84M-0.1720SONNSonnet BioTherapeutics1.4085 of 5 stars$2.96-2.6%$30.00+913.5%+111.1%$2.01M$150,000.000.0012ENTOEntero Therapeutics0.8892 of 5 stars$0.42+2.9%N/AN/A$2.00MN/A0.009AKANAkandaN/A$1.39-0.7%N/A-95.9%$1.98M$2.51M0.00110 Related Companies and Tools Related Companies CMND Competitors DRMA Competitors NTBL Competitors GRTX Competitors JMAC Competitors MAAQ Competitors SLRX Competitors SONN Competitors ENTO Competitors AKAN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRFX) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRFX Stock Alerts